KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Novartis Ag (NVS) Accumulated Expenses (2017 - 2025)

Novartis Ag (NVS) has disclosed Accumulated Expenses for 9 consecutive years, with $1.0 billion as the latest value for Q4 2025.

  • Quarterly Accumulated Expenses rose 518.34% to $1.0 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.0 billion through Dec 2025, up 518.34% year-over-year, with the annual reading at $1.0 billion for FY2025, 518.34% up from the prior year.
  • Accumulated Expenses hit $1.0 billion in Q4 2025 for Novartis Ag, up from $169.0 million in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $1.1 billion in Q4 2022 to a low of $116.0 million in Q4 2023.
  • Historically, Accumulated Expenses has averaged $503.2 million across 5 years, with a median of $169.0 million in 2024.
  • Biggest five-year swings in Accumulated Expenses: skyrocketed 733.86% in 2022 and later tumbled 89.05% in 2023.
  • Year by year, Accumulated Expenses stood at $127.0 million in 2021, then soared by 733.86% to $1.1 billion in 2022, then crashed by 89.05% to $116.0 million in 2023, then surged by 45.69% to $169.0 million in 2024, then skyrocketed by 518.34% to $1.0 billion in 2025.
  • Business Quant data shows Accumulated Expenses for NVS at $1.0 billion in Q4 2025, $169.0 million in Q4 2024, and $116.0 million in Q4 2023.